Recombinant anti-p53 Nanobody, Clone # Nb139, COOH-terminal HA tag.Type: VHH single domainSource: E. ColiApplications: ELISA, Immunoprecipitation, Pull downClonality: Monoclonal

Background: p53 DBD VHH Antibody was produced in an alpaca with human recombinant p53 DNA-binding domain then cloned for recombinant production in E. Coli. p53 is a tetrameric transcription factor and tumor suppressor that controls numerous aspects of cellular behavior. Mutations in p53 are observed in over 50% of human cancers with several hot spot mutations occurring in the DNA binding domain of p53.

Recombinant anti-p53 Nanobody 139 was developed by Gulliver Biomed.

Storage

Store at -20°C upon arrival. For long term storage, aliquot and store at -80°C. Avoid repeated freeze/thaw cycles.

Publications

1) Bethuyne J, et al. (2014) A nanobody modulates the p53 transcriptional program without perturbing its functional architechture. Nucleic Acids Res; 42(20):12928-129382) Steels, A et al. (2018) Intracellular displacement of p53 using transactivation domain (p53 TAD) specific nanobodies. MAbs; 10(7):1045-10593) Steels, A et al. (2019) Nb-induced stabilisation of p53 in HPV-infected cells. Sci Rep; 9(1):12680

Keywords: p53, DNA-binding domain, DBD, nanobody, VHH, antibody, single domain

‘Nanobody’ and ‘nanobodies’ are registered trademarks of Ablynx N.V.